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Background: Prostate cancer (PCa) is the second most frequently diagnosed cancer in male. In South
Korea, PCa incidence has increased signiﬁcantly, while its mortality rate has decreased steadily. To
optimize the distribution of public medical resources, it is essential to analyze the contemporary
epidemiology of PCa.
Methods: National population data from the National Health Insurance Statistical Yearbook and the
annual report of national cancer registration and statistics in Korea were assessed. From the data, the
incidence, prevalence, and mortality rates of PCa were calculated. The data were presented with refer-
ence to other types of cancers occurring in various countries from different continents.
Results: From 2007 to 2013, PCa incidence doubled (from 5,516 per year to 10,855 per year), while its
prevalence in Korean men tripled (from 18,830 to 51,411) during the same period. The mortality rate
increased slightly, from 4.2 in 2000 to 5.9 in 2007 and 6.0 in 2013 (per 100,000, age adjusted). PCa
incidence increased signiﬁcantly faster in men aged < 70 years than in the older age group.
Conclusion: PCa prevalence in South Korea has increased signiﬁcantly, mainly due to the rise in its
incidence. As the country is facing major changes, including westernization of dietary habits and rapid
population aging, its prevalence would continue to increase in near future.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. All rights reserved.Introduction
Cancer is themost common cause of death in Korea. The number
of cancer patients in Korea is increasing, which was 218,735 in
2000, 425,281 in 2006, and 960,654 in 2010.1 Prostate cancer (PCa)
is the second most frequently diagnosed cancer in the world, ac-
counting for 15.0% of all cancer diagnoses.2 In South Korea, PCa
incidence has increased signiﬁcantly, partly due to the rise in
average life expectancy, westernized dietary habits, and increased
awareness of PCa screening.3,4 As the PCa incidence increased, the
proportion of nonmetastatic disease also increased,5 and markers
of tumor aggressivenessdprostate speciﬁc antigen (PSA), stages,
and Gleason scoreddropped.6 Partly on that account, cancer-
speciﬁc survival rates improved signiﬁcantly.4 Therefore, one can
expect that the prevalence rate of PCa in Korean men would havetional Health Insurance Cor-
edicine, 100, Ilsanro, Goyang,
iﬁc Prostate Society, Published bybeen changed too. Utilizing data from the National Health Insur-
ance Statistical Yearbook and the annual report of national cancer
registration and statistics in Korea, we analyzed the recent trends in
the incidence and prevalence of PCa.Materials and methods
From the annual report of national cancer registration and sta-
tistics in Korea in 20127 (http://ncc.re.kr/english/infor/kccr.jsp), we
gathered serial annual data on the incidence, prevalence, and
mortality rates of PCa from 1999 to 2012. In addition, population
data from 2007 to 2012 were gathered from the National Health
Insurance Statistical Yearbook1 (http://www.hira.or.kr/).Deﬁnitions of terms
The deﬁnitions are cited from the annual report of national
cancer registration and statistics in Korea in 2012.7Elsevier. All rights reserved.
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Fig. 2. Male cancer incidence by age group (25e85þ) in Korea. (A) Top ﬁve male
cancers in 2012. (B) Annual trends in prostate cancer incident, from 1999 to 2012. See
Table 2 for raw data. Original data available from the annual report of cancer statistics
in Korea in 2012.
Prostate Int 3 (2015) 99e102100Crude rate
The crude rate (CR), a rate based on the frequency of cancer in
the entire population, is calculated as follows:
Crude rateCRðper 100;000 person yearsÞ
¼ Number of events
Corresponding person years of observation 100;000
Standard population
The standard population provides age distributions to be used in
the estimation of age-adjusted rates. The Korean standard popu-
lation (year 2000) is used in this report. For international com-
parison, the world standard population is used.8
Age-standardized rate
An age-standardized rate is a weighted average of crude age-
speciﬁc rates, where the CRs are calculated for different age
groups and the weights are the proportions of persons in the cor-
responding age groups of a standard population. In this report,
rates were standardized to the Korean standard population or
World standard population.
Cumulative rate
The cumulative rate is the sum over each year of age of the age-
speciﬁc rates, taken from birth to the age of 74 years (the 0e74
rate).
Prevalent cases
As national cancer incidence can be estimated from 1999,
prevalent cases in this report are deﬁned as the number of cancer
patients alive on a certain day who had been diagnosed with the
disease since January 1, 1999. For example, cancer prevalent cases
on January 1, 2013 are the cancer patients who were diagnosed
between January 1, 1999 and December 31, 2012, and were alive on
January 1, 2013. Multiple primary cancer cases are countedmultiple
times.
Five-year prevalent cases
Five-year prevalent cases are deﬁned as the number of cancer
patients alive with the disease within the ﬁrst 5 years of diagnosis.
For example, 5-year cancer prevalent cases on January 1, 2012 are
the cancer patients who were diagnosed between January 1, 2008Stomach
Colon and rectum
Lung
Liver
Prostate
Thyroid
Pancreas
Kidney
Bladder
Gallbladder etc.
Others
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Fig. 1. Cancer incidence distribution by sites in males, in Korea in 2012. Original data
available from the annual report of cancer statistics in Korea in 2012. ASR, age-
standardized rate; CR, crude rate.and December 31, 2012, and were alive on January 1, 2013. In-
dividuals still alive 5 years after their diagnosis are considered
“cured.” In fact, the death rates of most cancer patients 5 years after
the diagnosis are close to those expected in the general population.Results
Incidence
PCa is ranked ﬁfth among all cancer incidences of major sites in
Korean men (Fig. 1). Divided in age groups, PCa incidence increasesOthers
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Fig. 3. International comparison of age-standardized cancer incidence rates in male
[The incidence rates all types of cancers except for skin cancer (standard population:
world standard population.2)]. Original data available from the annual report of cancer
statistics in Korea in 2012.
Table 1
Prostate cancer incidence rate in male, stratiﬁed by age group.a)
Age group (yr) 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999
All 36.8 36.0 32.2 30.1 26.7 22.5 18.3 15.3 14.0 10.9 8.4 7.5 5.5 6.1
25e29 0.1 0.1 0.1 e e e 0.1 e e 0.1 e e e e
30e34 0.0 0.1 0.1 0.3 e 0.1 0.0 e e e 0.1 0.2 0.1 0.0
35e39 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 e 0.1
40e44 0.5 0.9 1.0 0.4 0.6 0.7 0.5 0.7 0.4 0.3 0.4 0.1 0.1 0.1
45e49 3.2 3.2 3.1 2.8 2.8 2.0 2.5 1.4 0.8 1.2 1.5 0.9 1.2 1.2
50e54 12.8 12.6 12.5 13.1 11.4 9.7 7.4 7.1 5.4 3.7 4.3 2.7 2.9 3.3
55e59 41.3 40.7 38.4 39.0 36.3 31.6 26.7 21.8 20.1 16.1 13.0 11.4 8.0 8.6
60e64 112.1 115.6 98.3 93.4 90.9 83.0 70.1 57.8 56.6 44.1 33.6 29.8 20.1 23.2
65e69 211.6 228.8 212.9 201.7 180.7 149.9 127.1 116.2 112.9 75.8 62.5 57.3 47.6 49.3
70e74 308.6 319.3 296.0 296.8 270.2 247.3 201.3 169.0 172.1 148.5 106.4 115.3 77.2 100.1
75e79 377.3 390.6 369.8 363.0 346.9 310.1 280.6 239.7 236.0 211.4 169.3 168.5 126.2 140.3
80e84 379.3 387.1 351.9 373.2 353.2 319.5 300.5 285.6 248.2 242.6 227.7 184.4 167.7 203.7
85 363.8 284.9 371.8 304.9 311.0 306.0 275.5 283.1 254.6 240.0 217.1 202.8 150.3 183.2
a) Unit: cases, n per 100,000.
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Fig. 5. Annual trends in prostate cancer diagnosis and prevalence in Korea. Original
Han et al / Epidemiology of prostate cancer 101after 60 years of age, and in those aged > 65 years, PCa is ranked
fourth (Fig. 2A). International comparison of age-standardized
cancer incidence rates shows that the PCa incidence rate in South
Korea is similar to that in Japan (27.0 per 100,000 and 30.4 per
100,000, respectively), and still differ widely from the United States
or the United Kingdom (98.2 per 100,000 and 73.2 per 100,000,
respectively; Fig. 3).
Incidence rates of PCa in each age group from 1999 to 2012 are
described in Fig. 2 and Table 1. During that period, the fold-increase
rates of PCa incidence among the age groups differed signiﬁcantly.
For example, in men aged 80e84 years, the rate increased only
~1.5-fold (from 203.7 to 379.3). By contrast, in men aged 60e64
years and 50e54 years, the rate increased about 4-fold (from 23.2
to 112.1 and from 3.3 to 12.8, respectively).
Prevalence rate
Cancer prevalence rates among Korean men from January 1,
1999 to December 31, 2012 were calculated. The PCa prevalence
rate (CR) was 194.6 per 100,000, ranking third after stomach and
colorectal cancers (Fig. 4). The 5-year prevalence rate of PCa (CR)
was 140.1 per 100,000, also ranking third after stomach and colo-
rectal cancers. Since 2007, the PCa prevalence rate has increased
gradually (Fig. 5).Prevalence rate
5-year prevalence rate
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Fig. 4. Cancer prevalence/5-year cancer prevalence of major sites in male, 2012. Age
was adjusted to the Korean standard population. Original data available from the
annual report of cancer statistics in Korea in 2012. ASR, age-standardized rate.Mortality
In 2012, cancer was the leading cause of death in South Korea.
Among cancers of all sites, PCa mortality was ranked seventh
(Fig. 6), accounting for 3.1% of all causes of death in Korean men
(Table 2). The PCa mortality rate increased slightly from 4.2 in 2000
to 5.9 in 2007 and 6.0 in 2013 (per 100,000, age standardized;
Fig. 7). During the same period, the overall cancer mortality rate15,000
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Fig. 6. Mortalities from cancers of major sites in males, 2012. Original data available
from the annual report of cancer statistics in Korea in 2012.
data acquired from the annual report of cancer statistics in Korea in 2012 (2007e2011)
and the National Health Insurance Statistical Yearbook (2012 and 2013).
Table 2
Mortalities from cancers of major sites in male, 2012.a)
Sites Cases % CR
All cancers 46,620 100 184.5
Lung 12,175 26.2 48.3
Liver 8,494 18.3 33.7
Stomach 6,090 13.1 24.2
Colon and rectum 4,692 10.1 18.6
Pancreas 2,616 5.6 10.4
Gallbladder, etc. 1,818 3.9 7.2
Prostate 1,460 3.1 5.8
Esophagus 1,278 2.8 5.1
Non-Hodgkin lymphoma 927 2 3.7
Leukemia 919 2 3.6
a) Unit: cases, %, cases per 100,000.
CR, crude rate.
Fig. 7. Annual trends in prostate cancer mortality rates in Korea. Age was adjusted to
the Korean standard population. Original data available from the Statistics Korea
(http://kostat.go.kr).
Prostate Int 3 (2015) 99e102102decreased steadily, from 226.7 in 2000 to 196.4 in 2007 and 162.8 in
2013 (per 100,000, age standardized; Fig. 7).
Discussion
Statistics indicate that PCa incidence in South Korea is
increasing. In 2009, Choi and Park9 reported that the prevalence of
PCa is increasing more rapidly than that of all other major male
cancers. The result of our analysis is in line with their results,
adding that PCa incidence is especially high in the elderly Korean
population. The chance of Koreanmen getting a cancer during their
lifetime is 37.5%,7 and PCa accounts for 8.2% of the total cancer
diagnoses. Although the numbers are still lower than those of
Western countries, one can expect further expansion in near future,
considering the fast population aging that the world has ever
faced.10 In 2005, a mass screening program analysis reported that
the estimated PCa detection rate in men aged 55 years or older was
highest in Korea among Asian countries.11 While PCa incidence
varies signiﬁcantly across theworld, cancer-speciﬁc mortality is not
signiﬁcantly different between developed and underdeveloped
countries.8 Moreover, Asian population seems to exhibit a low PCa
mortality rate than the populations of other regions/races. Thus,
one can tell that PCa prevalence would not decrease but would
increase in South Korea.
An age-group analysis showed that PCa incidence in men aged <
70 years increased much faster than those aged  70 years. This
trend may reﬂect the change in PCa diagnosis patterndfrom
symptom based to PSA screening based.
The PCa mortality rate in South Korea did not decrease but
increased during the last decade. Recently, Baade et al12 reported
that the rates in Asia-Paciﬁc countries such as Singapore and Hong
Kong have also increased by ~1% per year in the past decade. By
contrast, the rate in Japan has decreased by 1% per year. Interest-
ingly, the 5-year survival rate of PCa patients in South Korea
improved dramatically from 55.9% (1993e1995) to 67.2%
(1996e2000), 80.1% (2001e2005), 90.2% (2006e2010), and most
recently, 92.3% (2008e2012).13 This discrepancy between the
trends of PCa survival rate and mortality rate may be explained by
increases in early diagnosis and overall incidence.14
One of the limitations of this study is the lack of clinical/path-
ologic stage data. Currently, such information is not available in the
national database. There are some reports on PCa stages from in-
dividual institutions, though. Song et al15 reported that from 1997
to 2006, the rate of localize PCa diagnosed in a single institution
increased from 56.8% to 75.4%, and clinical T1c disease increased
from 26.4% to 31.6%. Similarly, Lee et al5 reported that the rate
increased from 67% in 2006 to 79% in 2010. Kim et al6 studied thepreoperative PSA, pathological stage, and Gleason score trends in a
single institution, noting that all of them dropped signiﬁcantly from
2000 to 2011. PCa is the most frequently diagnosed male cancer in
many developed Western countries,2 and it may become the future
of Korea. Therefore, public policies and medical resource redistri-
bution plans should be prepared to adapt to the anticipating
changes.Conﬂicts of interest
No conﬂict of interest exist.References
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